Bexobrutideg Shows High Response Rates in CLL/SLL Across Treatment Lines
Bexobrutideg has demonstrated high clinical response rates across multiple treatment lines in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL), according to recent clinical data highlighted by OncLive. ... Read More